Dual Immunotherapy Edges Out Pembrolizumab in Cost-Effectiveness for MSI-High Colorectal Cancer
A new cost-effectiveness analysis finds nivolumab plus ipilimumab may offer greater quality-adjusted life years at lower cost than pembrolizumab as ...
Tag: nivolumab
Immune Side Effects May Signal Stronger Tumor Shrinkage and Longer Survival in Gastric Cancer
A Japanese study found that immune-related adverse events during checkpoint inhibitor therapy for advanced gastric cancer were independently linked to ...
Radiation or Surgery After Dual Immunotherapy Fails to Extend Survival in Metastatic Lung Cancer
The Phase III LONESTAR trial found that adding radiation or surgery after nivolumab plus ipilimumab did not improve survival in ...
Japanese Gastric Cancer Care Transformed by Immunotherapy Shift, 12-Year Data Show
A 12-year Japanese database study of 16,573 patients shows first-line nivolumab plus chemotherapy rapidly displaced cisplatin-based regimens in HER2-negative advanced ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!